Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924233 | 0.85 | KDM4E (0.38) | KDM4EFABP7FABP3LMNANAMPT | |
| SCHEMBL29900573 | 0.85 | FABP7 (0.53) | MC1RKDM4EFABP7FABP3HRH3 | |
| SCHEMBL23951748 | 0.84 | TACR1 (0.51) | — | |
| SCHEMBL29900624 | 0.82 | EPHX2 (0.47) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29900566 | 0.82 | EPHX2 (0.47) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29900665 | 0.80 | TRPV1 (0.39) | MC1RSMN1; SMN2 | |
| SCHEMBL29900723 | 0.80 | TNKS (0.49) | MC1RKDM4EALDH1A1GAAHTT | |
| SCHEMBL29900780 | 0.80 | TNKS (0.49) | MC1RKDM4EALDH1A1GAAHTT | |
| SCHEMBL29900714 | 0.80 | MC1R (0.39) | MC1RKDM4EFABP7FABP3HRH3 | |
| SCHEMBL23951695 | 0.79 | ROCK2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | MC1R 720/4885KDM4E 2961/4885FABP7 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.